Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)

CONCLUSION: The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers.PMID:33608144 | DOI:10.1016/j.ygyno.2021.02.016

Source: Gynecologic Oncology - February 20, 2021 Category: Cancer & Oncology Authors: M Friedlander C Benson R L O'Connell N Reed A Clamp R Lord D Millan S Nottley F Amant C Steer A Anand L Mileshkin P Beale S Banerjee N Bradshaw C Kelly K Carty L Divers L Alexander R Edmondson Source Type: research